clinical trial · NCT04629248
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
Hoffmann-La Roche·phase3·active not recruiting·n = 142
Primary Membranous NephropathyObinutuzumabTacrolimusMethylprednisoloneAcetaminophenDiphenhydramine
brief summary
This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).
started
Jun 25, 2021
primary completion
Dec 22, 2025
completion
Dec 21, 2027
last updated
Apr 7, 2026
official title
A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol